174672-58-3

Upstream product

• 177575-35-8 5-trimethylsilanylethynylthiophene-2-carboxylic acid methyl ester 
• 62224-19-5 5-bromo-2-thiophenecarboxylic acid methyl ester 
• 7311-63-9 5-bromothiophene-2-carboxylic acid 
• 881736-66-9 ethyl 5-(2-trimethylsilyl-ethyn-1-yl)-thiophene-2-carboxylate 

Downstream Products

• 1519035-42-7 C₅₂H₄₈Mo₂N₆O₈S 
• 1436861-03-8 Mo₂(2,4,6-triisopropyl benzoate)2(5-ethynylthiophene-2-carboxylate)2 
• 1436861-04-9 W₂(2,4,6-triisopropyl benzoate)2(5-ethynylthiophene-2-carboxylate)2 
• 1316652-58-0 5-ethynylthiophene-2-carboxylic acid 2-aminophenylamide 
• 1316651-80-5 C₂₄H₂₇N₅OS 
• 1316651-77-0 C₂₀H₂₃N₅OS 
• 1316651-74-7 C₁₉H₂₁N₅OS 
• 1316651-73-6 C₂₄H₁₉N₅OS 
• 1316651-72-5 C₂₄H₁₉N₅OS 
• 1316651-71-4 C₂₆H₂₁N₅O₂S 
• 1316651-68-9 C₂₆H₂₁N₅O₂S 
• 1316651-65-6 C₂₆H₂₁N₅OS 
• 1316651-64-5 C₂₆H₂₁N₅OS 
• 1316651-63-4 C₂₁H₁₉N₅O₂S 

Relevant academic research and scientific papers

D-π-A structured porphyrins for efficient dye-sensitized solar cells

In this study, new push-pull alkoxy-wrapped zinc porphyrin dyes with intramolecular donor-π-acceptor structures have been designed and synthesized for dye-sensitized solar cells (DSCs). The linkers based on thiophene or 2,3-dihydrothieno[3,4-b][1,4] dioxine with cyanoacetic acid can broaden the spectral response of porphyrins into the near-IR region (～850 nm), which is mainly attributed to the cyanoacetic acid group. However, porphyrins with cyanoacrylic acid as an anchoring group lead to a faster charge recombination rate at the dye-sensitized heterojunction interface, which lowers the device photovoltaic performance. By using porphyrins with a rigid π-linker feature structure that is 5-ethynylthiophene-2-carboxylic acid, highly efficient DSC devices with a power conversion efficiency of 9.5% can be obtained. Spectral, electrochemical, photovoltage transient decay and impedance measurements are performed to reveal the influence of π-conjugated linkers and anchoring groups upon the optoelectronic features of porphyrin dyes in DSCs.

Design and synthesis of novel organometallic dyes for NiO sensitization and photo-electrochemical applications

Two metallo-organic dyes were synthesized and used for NiO sensitization in view of their photoelectrochemical applications. The new dyes present an original π-conjugated structure containing the [Ru(dppe)2] metal fragment with a highly delocalized allenylidene ligand on one side and a σ-alkynyl ligand bearing an electron-rich group, i.e. a thiophene or triphenylamine unit, and one or two anchoring functions on the other side. The optoelectronic, electrochemical and photoelectrochemical properties of the dyes were systematically investigated. A broad photoresponse was observed with the absorption maximum at 600 nm. The X-ray crystal structure of one precursor was obtained to elucidate the structural conformation of the organometallic complexes and theoretical calculations were performed in order to address the photophysical properties of the new dyes. These photosensitizers were further implemented in NiO-based photocathodes and tested as photocurrent generators under pertinent aqueous conditions in association with [Co(NH3)5Cl]Cl2 as an irreversible electron acceptor. The dye-sensitized photocathodes provided good photocurrent densities (40 to 60 μA cm-2) at neutral pH in phosphate buffer and a high stability was observed for the two dyes.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Using the same hydroxamic acid derivative and HDAC8 inhibitor (by machine translation)

Disclosed are: a compound which is capable of inhibiting the function of HDAC8; and an HDAC8 inhibitor. Specifically disclosed is a hydroxamic acid derivative which is characterized by being composed of a compound represented by general formula (1) (wherein X represents an aromatic substituent or an optionally substituted 3-8 membered ring, and n represents an integer of 0-20), or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries

To find HDAC8-selective inhibitors, we designed a library of HDAC inhibitor candidates, each containing a zinc-binding group that coordinates with the active-site zinc ion, linked via a triazole moiety to a capping structure that interacts with residues on the rim of the active site. These compounds were synthesized by using click chemistry. Screening identified HDAC8-selective inhibitors including C149 (IC50 = 0.070 μM), which was more potent than PCI-34058 (6) (IC50 = 0.31 μM), a known HDAC8 inhibitor. Molecular modeling suggested that the phenylthiomethyl group of C149 binds to a unique hydrophobic pocket of HDAC8, and the orientation of the phenylthiomethyl and hydroxamate moieties (fixed by the triazole moiety) is important for the potency and selectivity. The inhibitors caused selective acetylation of cohesin in cells and exerted growth-inhibitory effects on T-cell lymphoma and neuroblastoma cells (GI50 = 3-80 μM). These findings suggest that HDAC8-selective inhibitors have potential as anticancer agents.

An unexpected example of protein-templated click chemistry

(Figure Presented) It all happened with a click: In a search for histone deacetylase (HDAC) inhibitors using in situ click chemistry, the first example of protein-Cu acceleration of the azide-alkyne cycloaddition reaction was uncovered. The copper center

SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS

The present invention relates to new substituted glycinamides of general formula (I) wherein D, M, R3, R4 and R5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

FACTOR XA INHIBITORS

The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Novel substituted thiophenecarboxamides, their preparation and their use as medicaments

The present invention relates to novel substituted thiophene-2-carboxamides of the general formula in which A, Ar and R1 to R5 are as defined in Claim 1, their tautomers, their enantiomers, their diastereomers, their mixtures and the